These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 87616)

  • 1. Improvement in iron status and liver function in patients with transfusional iron overload with long-term subcutaneous desferrioxamine.
    Hoffbrand AV; Gorman A; Laulicht M; Garidi M; Economidou J; Georgipoulou P; Hussain MA; Flynn DM
    Lancet; 1979 May; 1(8123):947-9. PubMed ID: 87616
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of iron overload in adults with continuous parenteral desferrioxamine.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Am J Med; 1977 Dec; 63(6):958-66. PubMed ID: 605917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of dose, time, and ascorbate on iron excretion after subcutaneous desferrioxamine.
    Hussain MA; Green N; Flynn DM; Hoffbrand AV
    Lancet; 1977 May; 1(8019):977-9. PubMed ID: 67469
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
    Daar S; Pathare AV
    Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of iron overload due to repeated transfusions with subcutaneous infusions of desferrioxamine (author's transl)].
    Girot R; Thévenin M; Bouveret JP; Jeannel F; Rymer JC
    Arch Fr Pediatr; 1980 Apr; 37(4):241-7. PubMed ID: 7406638
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Subcutaneous infusion and intramuscular injection of desferrioxamine in patients with transfusional iron overload.
    Hussain MA; Green N; Flynn DM; Hussein S; Hoffbrand AV
    Lancet; 1976 Dec; 2(7998):1278-80. PubMed ID: 63749
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intravenous and subcutaneous desferrioxamine therapy in children with severe iron overload.
    Janka GE; Möhring P; Helmig M; Haas RJ; Betke K
    Eur J Pediatr; 1981 Nov; 137(3):285-90. PubMed ID: 7318841
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of continuous desferrioxamine administration in adults with transfusional hemosiderosis.
    Cooper B; Bunn HF; Propper RD; Nathan DG; Rosenthal DS; Moloney WC
    Trans Assoc Am Physicians; 1977; 90():335-41. PubMed ID: 611665
    [No Abstract]   [Full Text] [Related]  

  • 9. Non-transferrin-bound iron in long-term transfusion in children with congenital anemias.
    Wang WC; Ahmed N; Hanna M
    J Pediatr; 1986 Apr; 108(4):552-7. PubMed ID: 3083076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous desferrioxamine: the effect of three years' treatment on liver, iron, serum ferritin, and comments on echocardiography.
    Flynn DM; Hoffbrand AV; Politis D
    Birth Defects Orig Artic Ser; 1982; 18(7):347-53. PubMed ID: 6819017
    [No Abstract]   [Full Text] [Related]  

  • 11. Iron absorption in iron-loading anaemias: Effect of subcutaneous desferrioxamine infusions.
    Pippard MJ; Callender ST; Warner GT; Weatherall DJ
    Lancet; 1977 Oct; 2(8041):737-9. PubMed ID: 71542
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of transfusional iron overload before and during iron chelation by magnetic resonance imaging of the liver and determination of serum ferritin in adult non-thalassaemic patients.
    Jensen PD; Jensen FT; Christensen T; Ellegaard J
    Br J Haematol; 1995 Apr; 89(4):880-9. PubMed ID: 7772526
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Continuous high-dose intravenous desferrioxamine treatment for iron overload.
    Sidi Y; Shaklai M; Liban E; Pinkhas J
    Isr J Med Sci; 1981 May; 17(5):348-51. PubMed ID: 7263191
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of the ferritin/alanine aspartate transaminase ratio as an iron overload marker independent of liver cell damage.
    Triadou P; Regnat-Lusinchi A; Girot R
    Eur J Haematol; 1989 Nov; 43(5):423-7. PubMed ID: 2612615
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation in transfusion-dependent thalassemia with chronic hepatitis.
    De Virgiliis S; Cossu P; Sanna G; Frau F; Loi E; Lobrano R; Nucaro A; Toccafondi C; Cornacchia G; Loi A; Cao A
    Acta Haematol; 1982; 67(1):49-56. PubMed ID: 6800202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload.
    Araujo A; Kosaryan M; MacDowell A; Wickens D; Puri S; Wonke B; Hoffbrand AV
    Br J Haematol; 1996 Jun; 93(4):835-7. PubMed ID: 8703813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Iron burden in sickle cell anemia.
    O'Brien RT
    J Pediatr; 1978 Apr; 92(4):579-82. PubMed ID: 633016
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of subcutaneous desferrioxamine on iron balance in young thalassemia major patients.
    De Virgiliis S; Cossu P; Toccafondi C; Sanna G; Frau F; Lobrano R; Cornacchia G; Nucaro A; Loi A; Bertolino F; Cao A
    Am J Pediatr Hematol Oncol; 1983; 5(1):73-7. PubMed ID: 6859457
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term administration of desferrioxamine in thalassaemia major.
    Seshadri R; Colebatch JH; Gordon P; Ekert H
    Arch Dis Child; 1974 Aug; 49(8):621-6. PubMed ID: 4278421
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients.
    Olivieri NF; Koren G; Hermann C; Bentur Y; Chung D; Klein J; St Louis P; Freedman MH; McClelland RA; Templeton DM
    Lancet; 1990 Nov; 336(8726):1275-9. PubMed ID: 1978115
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.